Pay in 4 interest-free payments of $6.27 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
:
The combination therapy showed promising antitumor efficacy, particularly in models with elevated HIF-1 and TGF- levels, suggesting that simultaneous inhibition of EGFR, VEGF, and hypoxia-related pathways can synergistically suppress tumor progression and may represent a viable strategy for treating resistant EGFR-mutant NSCLC (228)
Be the first to Write a Review for this item!
Human side effects are limited to transient headache, nausea, and vertigo in a small percentage of users (typically when the peptide is administered too rapidly)
US$ 29.41
US$ 27.93
US$ 22.36
US$ 20.14
